시장보고서
상품코드
1628899

암태아성 항원 시장 : 성별, 용도별, 최종사용자별, 국가별, 지역별 - 산업 분석, 시장 규모 및 점유율, 예측(2024-2032년)

Carcinoembryonic Antigen Market, By Gender, By Application, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 316 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포트 하이라이트

암태아성 항원 시장 규모는 2023년에 22억 1,550만 달러에 달하며, 2024-2032년에 CAGR 6.50%로 확대

암태아성 항원 시장 역학

암이환율의 상승

암 발병률이 증가함에 따라 암태아성 항원() 시장이 향후 활성화될 것으로 예상됩니다. 비정상 세포의 무질서한 발달과 확산은 암의 특징입니다. 암은 고령화, 유전적 소인, 환경오염물질, 생활습관 선택의 결과로 점점 더 흔해지고 있습니다. 종양 표지자인 암태아성 항원(CEA: carcinoembryonic antigen)은 암의 경과와 치료 효과를 추적하는 데 사용됩니다. 예를 들어 미국에 본부를 둔 정부 간 기구인 세계보건기구(WHO)는 2024년 2월, 2050년에는 약 3,500만 건의 신규 암 사례가 발생할 것으로 예상되며, 이는 2022년 예측치 2,000만 건보다 77% 증가한다고 밝혔습니다. 이처럼 암 발병률 증가로 인해 암태아성 항원 시장은 확대되고 있습니다.

암태아 항원 시장 : 주요 고려사항

당사의 리서치 애널리스트들이 공유한 분석에 따르면 세계 암태아 항원 시장은 예측 기간(2024-2032년) 동안 약 6.50%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예상됩니다.

성별로는 남성 카테고리가 2023년에 가장 높은 시장 점유율을 보였습니다.

용도별로는 소화기암이 2023년 주요 부문으로 꼽혔습니다.

지역별로는 2023년 북미가 주요 수입원이 되었습니다.

암태아성 항원 시장 : 세분화 분석

세계 암태아 항원 시장은 성별, 애플리케이션, 최종사용자 및 지역에 따라 세분화됩니다.

용도별로는 폐암, 소화기암(대장암, 식도암, 간암, 췌장암, 위암, 항문암, 담낭암), 유방암, 난소암, 전립선암, 갑상선암으로 나뉘며, 2023년에는 소화기암 카테고리가 시장을 지배할 것으로 예측됩니다. 전 세계에서 대장암, 위암, 췌장암은 장암 중 가장 흔한 유형입니다. 이들 질환의 높은 유병률과 공격적인 특성으로 인해 효율적인 진단 및 모니터링 방법의 필요성이 증가하고 있으며, CEA는 이들 질환의 중요한 바이오마커로 작용하고 있습니다. 또한 나이가 들수록 위험도가 증가하므로 특히 선진국의 인구 고령화는 소화관 악성 종양의 유병률 증가에 기여하고 있으며, CEA 검사에 대한 수요는 이러한 인구 추세로 인해 더욱 증가하여 소화기암 분야의 관련성을 더욱 확고히 하고 있습니다.

암태아 항원 시장은 병원, 종양 클리닉, 진단 실험실, 연구센터, 학술기관과 같은 최종사용자 부문으로 나뉘어져 있으며, 2023년 병원 부문의 매출은 병원 부문의 매출입니다. 암 진단, 치료 및 감시의 주요 장소는 CEA 검사가 일반적으로 사용되는 병원이며, CEA 검사의 병원 사용은 전 세계 암 발병률 증가에 따른 모니터링 및 진단 툴에 대한 수요가 증가함에 따라 증가하고 있습니다. 은 병원이 숙련된 직원과 최첨단 진단 툴을 자주 사용할 수 있는 경우 더욱 촉진됩니다. 병원의 일상적인 모니터링과 암 환자의 조기 발견에 대한 강조가 이 부문의 성장에 기여하고 있습니다.

암태아 항원 시장 : 지역별 분석

지역적으로 암태아 항원 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에서 널리 퍼져 있습니다. 이 지역은 비즈니스를 가져 오는 국가별로 더 세분화됩니다.

북미의 암태아 항원 시장은 높은 암 발병률, 정교한 의료 시스템, 막대한 R&D 비용으로 인해 전 세계에서 우위를 점하고 있습니다. 미국 암 협회는 2023년까지 북미에서 1,900만 명이 암 진단을 받을 것으로 예상하고 있으며, CEA 및 기타 종양 마커는 이러한 높은 발병률로 인해 높은 수요가 있을 것으로 예상하고 있습니다. 또한 Abbott Laboratories, Roche Diagnostics 등 북미에 기반을 둔 많은 대형 진단 의약품 회사들이 이러한 수요 증가에 대응하기 위해 지속적으로 제품 라인을 개발 및 확장하고 있습니다.

그러나 향후 수년간 아시아태평양의 암태아성 항원 시장은 암 발병률 증가, 의료비 상승, 암 조기 발견에 대한 인식 증가 등의 요인으로 인해 크게 성장할 것으로 예상됩니다. 중국, 인도, 일본은 인구가 많고 암 발병률이 높기 때문에 이러한 확대의 최전선에 있습니다. 국제암연구소(IARC)에 따르면 2020년 아시아는 전 세계 암 환자의 약 49.3%%를 차지할 것으로 예상됩니다. 이 지역 시장 확대를 더욱 촉진하는 것은 의료 시설을 강화하고 CEA와 같은 조기 진단 검사를 장려하는 정부 프로그램입니다.

암태아성 항원 시장 : 경쟁 구도

암태아성 항원 시장은 Quest Diagnostics, Thermo Fisher Scientific, Boster Biological Technology, Abcam Limited, Creative Diagnostics, F. Hoffmann-La Roche Ltd 등 대기업 사이의 치열한 경쟁에 의해 촉진되고 있습니다. 이들 기업은 광범위한 포트폴리오와 탄탄한 판매망을 활용하면서 암태아성 항원 검사의 정확도와 가격을 개선하기 위해 연구개발에 투자하고 있습니다. 면역 분석과 현장 진단의 발전을 통해 신생 기업도 업계를 주도하고 있습니다. 또한 기술 개발과 암의 조기 발견 및 모니터링에 대한 관심이 높아지면서 시장 수요를 견인하고 기존 및 신흥 산업 모두에 문호를 개방하고 있습니다. 예를 들어 2023년 12월 사노피는 tusamitamab ravtansine의 세계 과학 개발 프로젝트를 중단할 예정입니다. 이미 치료를 받고 있는 전이성 비편평상피성 비소세포폐암(NSCLC) 환자를 대상으로 투사미타맙 라브탄신을 단독요법으로 도세탁셀과 비교 평가하는 CARMEN-LC03 임상 3상 시험이 이번 결정의 원인입니다.

목차

제1장 암태아성 항원 시장 개요

  • 조사 범위
  • 시장 추정 기간

제2장 개요

  • 시장 내역
  • 경쟁 인사이트

제3장 암태아성 항원의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장의 향후 동향

제4장 암태아성 항원 시장 : 산업 분석

  • PEST 분석
  • Porter's Five Forces 분석
  • 시장 성장 전망 : 지도제작
  • 규제 체제 분석

제5장 암태아성 항원 시장 : COVID-19의 영향 분석

  • COVID-19 이전의 영향 분석
  • COVID-19 이후의 영향 분석

제6장 암태아성 항원 시장 구도

  • 암태아성 항원 시장 점유율 분석(2023년)
  • 주요 제조업체별 내역 데이터
    • 기존 기업의 분석
    • 신규 기업의 분석

제7장 암태아성 항원 시장 : 성별

  • 개요
    • 부문별 점유율 분석 : 성별
    • 남성
    • 여성

제8장 암태아성 항원 시장 : 용도별

  • 개요
    • 부문별 점유율 분석 : 용도별
    • 폐암
    • 소화기암
      • 대장암
      • 식도암
      • 간암
      • 췌장암
      • 위암
      • 항문암
      • 담낭암
    • 유방암
    • 난소암
    • 전립선암
    • 갑상선암

제9장 암태아성 항원 시장 : 최종사용자별

  • 개요
    • 부문별 점유율 분석 : 최종사용자별
    • 병원
    • 종양과클리닉
    • 진단 검사실
    • 연구 센터·학술기관

제10장 암태아성 항원 시장 : 지역별

  • 서론
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 인도
    • 중국
    • 한국
    • 일본
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제11장 주요 벤더 분석 : 암태아성 항원 업계

  • 경쟁 대시보드
  • 기업 개요
    • Boster Biological Technology
    • Abcam Limited
    • Creative Diagnostics
    • Aviva Systems Biology Corporation
    • AdvaCare Pharma
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Omega Diagnostics Ltd.
    • Medix Biochemica
    • RayBiotech, Inc.
    • Diazyme Laboratories Inc.
    • Quest Diagnostics Incorporated
    • Others

제12장 애널리스트의 전방위 전망

KSA 25.02.11

REPORT HIGHLIGHT

Carcinoembryonic Antigen Market size was valued at USD 2,215.5 Million in 2023, expanding at a CAGR of 6.50% from 2024 to 2032.

The endodermal epithelial cells of the embryo contain carcinoembryonic antigen (CEA). The fluids of the fetus, embryo, and gastrointestinal tract contain a glycoprotein called carcinoembryonic antigen. Carcinoembryonic antigen is also present in trace amounts in the blood, gastrointestinal cells, and colon mucosal cells. Additionally, the test can be used to diagnose and treat cancers like ovarian, lung, liver, colorectal, gastrointestinal, or colon cancers, as well as breast cancer. The market is expected to rise as a result of rising cancer incidence, an ageing population, and increased awareness. Over the past ten years, there has been a notable increase in the yearly number of cancer diagnoses worldwide. Additionally, as life expectancy rises, more people will receive a diagnosis during their lifetime, which will fuel market expansion.

Carcinoembryonic Antigen Market- Market Dynamics

Rising Incidence of Cancer

It is anticipated that the rising cases of cancer will fuel the market for carcinoembryonic antigens in the future. Uncontrolled development and spread of aberrant cells is a hallmark of cancer. Cancer is becoming common as a result of ageing populations, genetic predispositions, environmental pollutants, and lifestyle choices. The tumour marker carcinoembryonic antigen (CEA) is used to track the course of cancer and the efficacy of treatment. For instance, the World Health Organization (WHO), an intergovernmental agency based in the United States, stated in February 2024 that around 35 million new cases of cancer are expected to occur in 2050, a 77% increase from the 20 million cases forecast in 2022. Thus, the carcinoembryonic antigen market is expanding due to the increase in cancer incidence.

Carcinoembryonic Antigen Market- Key Insights

As per the analysis shared by our research analyst, the global Carcinoembryonic Antigen Market is estimated to grow annually at a CAGR of around 6.50% over the forecast period (2024-2032)

Based on gender segmentation, the male category was predicted to show the maximum market share in the year 2023

Based on application segmentation, the gastrointestinal cancer was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Carcinoembryonic Antigen Market- Segmentation Analysis:

The Global Carcinoembryonic Antigen Market is segmented on the basis of Gender, Application, End-user, and Region.

By application, the market is divided into Lung cancer, Gastrointestinal cancer (Colorectal cancer, Esophageal cancer, Liver cancer, Pancreatic cancer, Stomach cancer, Anal cancer, Gall bladder cancer), Breast cancer, Ovarian cancer, Prostate cancer, and Thyroid cancer. In 2023, the market was dominated by the gastrointestinal cancer category. Globally, colon, stomach, and pancreatic cancers are among the most common types of intestinal cancers. The need for efficient diagnostic and monitoring methods is fueled by their high prevalence and aggressive nature, with CEA acting as a crucial biomarker for these disorders. Furthermore, because the risk increases with age, the ageing population-especially in developed regions-contributes to the increased prevalence of gastrointestinal malignancies. The demand for CEA testing is further increased by this demographic trend, which further solidifies the gastrointestinal cancer segment's relevance.

The market for carcinoembryonic antigens is divided into end-user segments, including Hospitals, Oncology clinics, Diagnostic laboratories, Research centres and academic institutes. Revenue for the hospitals' segment in 2023 was. The main locations for cancer diagnosis, treatment, and surveillance are hospitals, where CEA testing is commonly used. Hospital usage of CEA tests is increasing as a result of the increased demand for monitoring and diagnostic tools due to the rising incidence of cancer worldwide. The accurate and effective use of CEA testing is further facilitated by hospitals' frequent access to trained staff and cutting-edge diagnostic tools. The focus on routine hospital monitoring and early detection of cancer patients contributes to the segment's growth.

Carcinoembryonic Antigen Market- Geographical Insights

Geographically, the Carcinoembryonic Antigen Market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

The market for carcinoembryonic antigen in North America is dominated worldwide due to the region's high cancer incidence, sophisticated healthcare system, and significant R&D expenditures. Due to the fact that early cancer identification and monitoring are essential for successful treatment, the market in this region is growing. In 2023, the American Cancer Society projected that 1.9 million new cases of cancer will be diagnosed in North America. CEA and other tumour markers are in high demand due to this high incidence rate. Furthermore, a number of major diagnostics companies, such as Abbott Laboratories and Roche Diagnostics, are based in North America and are constantly developing and broadening their product lines to meet this rising demand.

However, over the upcoming years, the carcinoembryonic antigen market in the Asia-Pacific region is expected to rise significantly due to factors such as rising cancer prevalence, rising healthcare costs, and increased awareness of early cancer detection. China, India, and Japan are at the forefront of this expansion because of their sizable populations and greater rates of cancer. In 2020, Asia accounted for around 49.3% of all cancer cases worldwide, as per the International Agency for Research on Cancer (IARC). Further driving market expansion in the area are government programs to enhance healthcare facilities and encourage early diagnostic testing, such as CEA.

Carcinoembryonic Antigen Market- Competitive Landscape:

The carcinoembryonic antigen market is driven by fierce competition between major firms, including Quest Diagnostics, Thermo Fisher Scientific Inc., Boster Biological Technology, Abcam Limited, Creative Diagnostics, and F. Hoffmann-La Roche Ltd, among others. These companies invest in R&D to improve the precision and affordability of carcinoembryonic antigen tests while utilizing their broad portfolios and robust distribution networks. Through advancements in immunoassays and point-of-care diagnostics, emerging businesses are also boosting the industry. Furthermore, technical developments and the growing emphasis on early cancer detection and monitoring are driving market demand and opening doors for both established and up-and-coming competitors. For instance, in December 2023, the global scientific development project for tusamitamab ravtansine is being halted by Sanofi. The Phase 3 CARMEN-LC03 trial, which evaluates tusamitamab ravtansine as a monotherapy in comparison to docetaxel in patients with metastatic non-squamous non-small cellular lung cancer (NSCLC) who have already received treatment, is the source of this decision.

Recent Developments:

April 2024: The renowned AI TechBio business and precision medicine pioneer Caris DiscoveryTM, the research arm of Caris Life Sciences(R) (Caris), announced a long-term strategic partnership with Merck KGaA, headquartered in Darmstadt, Germany. In the United States and Canada, Merck KGaA, which operates its healthcare business under the name EMD Serono, will partner with Caris DiscoveryTM to accelerate the search for and development of superior antibody-drug conjugates (ADC) for cancer patients.

March 2024: The FDA designated A2 Biotherapeutics Inc. as an orphan medication for A2B530, a new cell therapy designed to treat colorectal cancer in patients with germline heterozygous HLA-A02 positivity whose tumours express CEA but no longer express HLA-A02. This designation encourages the development of the medication. It provides incentives for progress in the treatment of colorectal cancer by highlighting its potential to address a major unmet need in this particular patient population.

July 2023: To determine the hepatitis C virus (HCV) antigen and antibody status simultaneously and independently from a single human plasma or blood sample, Roche Diagnostics India introduced the Elecsys HCV Duo, the country's first completely automated immunoassay. This innovative diagnostic technology simplifies the procedure for medical professionals and improves patient outcomes, representing a major advancement in HCV identification.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Boster Biological Technology
  • Abcam Limited
  • Creative Diagnostics
  • Aviva Systems Biology Corporation
  • AdvaCare Pharma
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Omega Diagnostics Ltd.
  • Medix Biochemica
  • RayBiotech, Inc.
  • Diazyme Laboratories Inc.
  • Quest Diagnostics Incorporated
  • Others

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY GENDER- MARKET ANALYSIS, 2019 - 2032

  • Male
  • Female

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Lung cancer
  • Gastrointestinal cancer
  • Colorectal cancer
  • Esophageal cancer
  • Liver cancer
  • Pancreatic cancer
  • Stomach cancer
  • Anal cancer
  • Gall bladder cancer
  • Breast cancer
  • Ovarian cancer
  • Prostate cancer
  • Thyroid cancer

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Oncology clinics
  • Diagnostic laboratories
  • Research centres and academic institutes

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Carcinoembryonic Antigen Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Carcinoembryonic Antigen Market Snippet by Gender
    • 2.1.2. Carcinoembryonic Antigen Market Snippet by Application
    • 2.1.3. Carcinoembryonic Antigen Market Snippet by End-user
    • 2.1.4. Carcinoembryonic Antigen Market Snippet by Country
    • 2.1.5. Carcinoembryonic Antigen Market Snippet by Region
  • 2.2. Competitive Insights

3. Carcinoembryonic Antigen Key Market Trends

  • 3.1. Carcinoembryonic Antigen Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Carcinoembryonic Antigen Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Carcinoembryonic Antigen Market Opportunities
  • 3.4. Carcinoembryonic Antigen Market Future Trends

4. Carcinoembryonic Antigen Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Carcinoembryonic Antigen Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Carcinoembryonic Antigen Market Landscape

  • 6.1. Carcinoembryonic Antigen Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Carcinoembryonic Antigen Market - By Gender

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Gender, 2023 & 2032 (%)
    • 7.1.2. Male
    • 7.1.3. Female

8. Carcinoembryonic Antigen Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 8.1.2. Lung cancer
    • 8.1.3. Gastrointestinal cancer
      • 8.1.3.1. Colorectal cancer
      • 8.1.3.2. Esophageal cancer
      • 8.1.3.3. Liver cancer
      • 8.1.3.4. Pancreatic cancer
      • 8.1.3.5. Stomach cancer
      • 8.1.3.6. Anal cancer
      • 8.1.3.7. Gall bladder cancer
    • 8.1.4. Breast cancer
    • 8.1.5. Ovarian cancer
    • 8.1.6. Prostate cancer
    • 8.1.7. Thyroid cancer

9. Carcinoembryonic Antigen Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Oncology clinics
    • 9.1.4. Diagnostic laboratories
    • 9.1.5. Research centres and academic institutes

10. Carcinoembryonic Antigen Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Carcinoembryonic Antigen Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Carcinoembryonic Antigen Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Carcinoembryonic Antigen Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Carcinoembryonic Antigen Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Carcinoembryonic Antigen Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Carcinoembryonic Antigen Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Boster Biological Technology
    • 11.2.2. Abcam Limited
    • 11.2.3. Creative Diagnostics
    • 11.2.4. Aviva Systems Biology Corporation
    • 11.2.5. AdvaCare Pharma
    • 11.2.6. F. Hoffmann-La Roche Ltd.
    • 11.2.7. Thermo Fisher Scientific Inc.
    • 11.2.8. Omega Diagnostics Ltd.
    • 11.2.9. Medix Biochemica
    • 11.2.10. RayBiotech, Inc.
    • 11.2.11. Diazyme Laboratories Inc.
    • 11.2.12. Quest Diagnostics Incorporated
    • 11.2.13. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제